Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4308303 | 0.91 | HIF1A (0.51) | HIF1AMEN1RAB9AKMT2AEPAS1 | |
| SCHEMBL3145341 | 0.88 | RAB9A (0.48) | HIF1AMEN1RAB9AKMT2AEPAS1 | |
| SCHEMBL4780052 | 0.86 | CNR1 (0.45) | HIF1AMEN1RAB9AKMT2AEPAS1 | |
| SCHEMBL3147963 | 0.83 | HIF1A (0.51) | HIF1AMEN1RAB9AKMT2AEPAS1 | |
| SCHEMBL3152851 | 0.81 | HIF1A (0.54) | HIF1AEPAS1ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL3143193 | 0.77 | HIF1A (0.52) | HIF1AMEN1RAB9AKMT2AEPAS1 | |
| SCHEMBL15552108 | 0.76 | RAB9A (0.56) | RAB9AKMT2ACHEK2ALDH1A1CYP1A2 | |
| SCHEMBL13576958 | 0.75 | CASP2 (0.55) | HIF1ARAB9AKMT2AEPAS1ALDH1A1 | |
| SCHEMBL13576905 | 0.73 | HIF1A (0.60) | HIF1ARAB9AEPAS1ALDH1A1CYP1A2 | |
| SCHEMBL13576959 | 0.71 | HIF1A (0.40) | HIF1AEPAS1ALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304448-B2 | Method for the treatment of metabolic disorder containing benzazole derivatives as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-11-06 | — | — | US | claimed |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY | 2010-03-25 | — | — | US | claimed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | claimed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8394799-B2 | Compounds that inhibit HIF-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2013-03-12 | — | — | US | disclosed |
| US-8304448-B2 | Method for the treatment of metabolic disorder containing benzazole derivatives as an active ingredient | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-11-06 | — | — | US | disclosed |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY | 2010-03-25 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306078-A1 | COMPOUNDS THAT INHIBIT HIF-1 ACTIVITY, THE METHOD FOR PREPARATION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM AS AN EFFECTIVE COMPONENT | HIF1AN, HIF1A, VHL | HIF1A 2/4885MEN1 3620/4885RAB9A 884/4885 |
| US-20100076039-A1 | COMPOSITION FOR THE PREVENTION AND TREATMENT OF METABOLIC DISORDER CONTAINING BENZAZOLE DERIVATIVES AS AN ACTIVE INGREDIENT | DGAT2, DGAT1, ACAT1 | HIF1A 4095/4885MEN1 3885/4885RAB9A 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.